{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:58:30Z","timestamp":1753891110456,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Leuk-CTL-001 (EudraCT n. 2019-003362-41) is a Phase I\/II clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes (CTLs) for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation (HCT). The prognosis for children affected by acute leukemia and transplanted in an advanced disease stage, in the presence of measurable minimal residual disease (MRD) or with unfavorable cytogenetic abnormalities, is still poor and often less than 50%. Adoptive cell therapy based on the infusion of donor-derived CTLs able to recognize patients\u2019 leukemia blasts (LB) is a promising approach to control leukemia relapse after allogeneic HCT. We previously described a procedure for <jats:italic>ex vivo<\/jats:italic> generating and expanding large numbers of donor-derived anti-leukemia CTL in compliance with Good Manufacturing Practice (GMP). The analysis of all batches of anti-leukemia CTLs produced so far documented that the majority of effector cells were CD3+\/CD8+ cells, with a memory\/terminal activated phenotype displaying efficient capacity to lyse patients\u2019 LB and to secrete IFN\u03b3 and TNF\u03b1 in response to leukemia cells. The Leuk-001 trial explores the safety of infusion of escalating doses of anti-leukemia CTLs in a cohort of high-risk relapse pediatric patients given haploidentical HCT for acute leukemia, starting within 60 days after transplantation. The safety is evaluated in terms of incidence of acute and chronic graft versus host disease (GVHD). The secondary objective is the evaluation of efficacy defined as cumulative incidence of relapse.<\/jats:p><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.isrctn.com\/<\/jats:uri>, identifier ISRCTN13301166; <jats:uri>https:\/\/clinicaltrials.gov\/<\/jats:uri>, NCT06865352.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1601961","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:10:53Z","timestamp":1749183053000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I\/II clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation: study rational and design"],"prefix":"10.3389","volume":"16","author":[{"given":"Daniela","family":"Montagna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Comoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Tanzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Montini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Moretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Taurino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Boghen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Panigari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Mina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Giorgiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Del Fante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Perotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491621","article-title":"Results of the AIEOP AML 2002\/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia","volume":"122","author":"Pession","year":"2013","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0153-1","article-title":"Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report","volume":"53","author":"Passweg","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-207001","article-title":"Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group","volume":"115","author":"Klingebiel","year":"2010","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861575","article-title":"Unrelated donor vs HLA-haploidentical \u03b1\/\u03b2 T-cell\u2013 and B-cell\u2013depleted HSCT in children with acute leukemia","volume":"132","author":"Bertaina","year":"2018","journal-title":"Blood"},{"key":"B6","unstructured":"Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.246","article-title":"Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002\/01 study","volume":"50","author":"Locatelli","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14523","article-title":"Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol","volume":"177","author":"Buldini","year":"2017","journal-title":"Br J Haematology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus\u2013targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"JCO"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.13792","article-title":"Current status of chimeric antigen receptor therapy for haematological Malignancies","volume":"172","author":"Maude","year":"2016","journal-title":"Br J Haematology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042150","article-title":"A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia","volume":"22","author":"Martino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.42","article-title":"Safer CARS","volume":"18","author":"Heslop","year":"2010","journal-title":"Mol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-017-0519-7","article-title":"Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia","volume":"10","author":"Fan","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1005457","article-title":"Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing","volume":"13","author":"Martinez-Cibrian","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-076844","article-title":"Graft-versus-leukemia effects associated with detectable Wilms tumor-1\u2013specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia","volume":"110","author":"Rezvani","year":"2007","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1116","article-title":"Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation","volume":"31","author":"Hofmann","year":"2013","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-230391","article-title":"Emergence of BCR-ABL\u2013specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment","volume":"115","author":"Riva","year":"2010","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00063-8","article-title":"Haploidentical transplantation for acute lymphoblastic leukemia in childhood","volume":"18","author":"Klingebiel","year":"2004","journal-title":"Blood Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248997","article-title":"Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens","volume":"115","author":"Warren","year":"2010","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-731091","article-title":"BCR-ABL\u2013specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors","volume":"129","author":"Comoli","year":"2017","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.4.1201","article-title":"Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes","volume":"94","author":"Falkenburg","year":"1999","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0530192100","article-title":"Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia","volume":"100","author":"Marijt","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0591","article-title":"Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction","volume":"66","author":"Montagna","year":"2006","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3359","article-title":"Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy","volume":"98","author":"Montagna","year":"2001","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(03)00230-3","article-title":"Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors","volume":"31","author":"Montagna","year":"2003","journal-title":"Exp Hematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/CJI.0b013e31816b1092","article-title":"Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines","volume":"31","author":"Daudt","year":"2008","journal-title":"J Immunotherapy"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.04.005","article-title":"Production of donor-derived cytotoxic T lymphocytes with potent anti-leukemia activity for adoptive immunotherapy in high-risk pediatric patients given haploidentical hematopoietic stem cell transplantation","volume":"26","author":"Tanzi","year":"2024","journal-title":"Cytotherapy"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021336","article-title":"TCR\u03b1\u03b2\/CD19 cell\u2013depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis","volume":"143","author":"Merli","year":"2024","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01232-x","article-title":"Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of \u03b1\u03b2 T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia","volume":"56","author":"Dunaikina","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2025.102176","article-title":"Novel CD62L depleted donor lymphocyte infusion with T-cell receptor alpha-beta depleted haploidentical hematopoietic stem cell transplantation in children","volume":"89","author":"Cheuk","year":"2025","journal-title":"Transplant Immunol"},{"key":"B39","article-title":"Anti-leukaemia CTL infusion for treatment of leukaemia relapse in children given allogeneic haematopoietic stem cell transplantation","volume":"39","author":"Montagna","year":"2007","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1601961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:10:54Z","timestamp":1749183054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1601961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1601961"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1601961","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"article-number":"1601961"}}